First Manhattan
HTGM

First Manhattan’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

First Manhattan’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-911
Closed -$53K – 1502
2020
Q1 		$53K Buy
911
+355
+64% +$34.8K ﹤0.01% 840
2019
Q4 		$70K Buy
+556
New +$75.3K ﹤0.01% 849

Other funds holding HTGM

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KM
Kalos Management Alpharetta, Georgia $46.6M AUM 11.52% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

First Manhattan's HTGM Position: Q2 2020 in Review

First Manhattan sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2020, closing a stake of 911 shares — an estimated $53K sold.

First Manhattan first reported a position in HTGM in Q4 2019 and held it in 2 quarters. The position peaked at $70K in Q4 2019. 28 funds tracked by Wall St. Rank hold HTGM as of Q2 2020.

  • First Manhattan reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • First Manhattan sold 911 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2020, an estimated $53K.
  • First Manhattan first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • First Manhattan's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $70K in Q4 2019.
  • 28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2020.

Based on First Manhattan's 13F filing for Q2 2020, filed 14 Aug 2020.